MedPath

AVI-6002

Generic Name
AVI-6002

Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus

Phase 1
Completed
Conditions
Ebola Hemorrhagic Fever
Interventions
Drug: Placebo
First Posted Date
2011-05-12
Last Posted Date
2012-03-28
Lead Sponsor
Sarepta Therapeutics, Inc.
Target Recruit Count
30
Registration Number
NCT01353027
Locations
🇺🇸

New Orleans Center for Clinical Research - Knoxville, Knoxville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath